You are here: Home > Healthcare Professional > Clinical Research > Our Researchers - Clinical Research Unit
Adjust font size:
CLINICAL RESEARCH

Dr Serena Low’s major research interests, based on our prospective KTPH Diabetic Nephropathy (DN) cohort and SMART2D cohort, include:

1. Epidemiology of Diabetic Nephropathy in Type 2 Diabetes – prevalence and risk factors for Diabetic Nephropathy in Singapore.
2. Onset and progression of Diabetic complications e.g. Transition probabilities of DN status.

Dr Liu Jian-Jun’s major research interests, based on our prospective KTPH Diabetic Nephropathy (DN) cohort and SMART2D cohort include:

1. Epidemiology of vascular complications in Type 2 Diabetes e.g. Ethnic differences in DN susceptibility.
2. Pathophysiology and early biomarkers (including metabolomics) of Diabetic Nephropathy.
3. Cross-talk between adipocytes, muscle, bone, blood vessel and kidney in obesity and diabetes. 

Dr Sharon Pek ’s research interests are biomarker discovery in Type 2 Diabetes and its complications by microRNA and metabolomics profiling. Her recent interest is in the development of translating genetic research studies to clinical utility and education in Familial Hypercholesterolemia. She is also involved in our peripheral arterial disease and diabetic neuropathy (SMART2D) project.

Dr Angela Moh’s major research interests primarily revolve around obesity and obesity-related disorders. Her work, based on our prospective Bariatric Surgery cohort, KTPH Diabetic Nephropathy (DN) cohort and SMART2D cohort includes:

1. Epidemiology of obesity and Diabetic Nephropathy
2. Metabolomics signature associated with early amelioration of type 2 diabetes after Bariatric Surgery
3. Protective genetic mechanisms against type 2 Diabetes in metabolically healthy obese adults

Dr Ang Su Fen’s research interest is in deciphering the genetic basis of diabetes and its complications, through the use of conventional and next-generation sequencing techniques, which will be clinically useful for disease prevention and diagnosis as well as personalizing medicine.

Major studies include:

1. Identifying known and novel genetic variants that contribute to Monogenic Diabetes/Maturity-onset Diabetes of the young (MODY) in our multi-ethnic Asian cohort.

2. Collaborative projects with external institutions (A*STAR):

a. Involving the use of our KTPH Diabetic Nephropathy (DN) cohort and SMART2D cohort to perform genome-wide association studies to identify causal genetic variants responsible for diabetes and its complications.
b. Involving the use of patient-derived stem cells from MODY study to determine the Molecular Etiology of MODY3.

Dr Resham Gurung’s current studies, based on our KTPH Diabetic Nephropathy (DN) cohort and SMART2D cohort aim to:

1. Identify the genetic markers associated with gastrointestinal adverse effects of Metformin in patients with type 2 diabetes.
2. Perform genome-wide association studies, in collaboration with A*STAR, to identify causal genetic variants associated with Diabetic Nephropathy.
3. Evaluate intrinsic aging related factors (telomere dynamics and mitochondria integrity) as potential biomarker for diabetes and complications.

Dr Zhang Xiao’s major research interests, based on our KTPH Diabetic Nephropathy (DN) cohort and SMART2D cohort, include:

1. Discovery of novel biomarkers in Type 2 Diabetes by genetic and non-genetic profiling
2. Study of familial aggregation of Diabetic Nephropathy and its risk factors (i.e., obesity, unfavourable lifestyle and social economic status)
3. Investigation of economic burden of Type 2 Diabetes in Singapore, including direct, indirect and intangible costs.